AFN-1252: Phase I data

Data from a double-blind, placebo-controlled, multiple ascending-dose, U.S. Phase I trial in 32 healthy volunteers showed that 200, 300 and 400 mg AFN-1252 once daily for 10 days was well tolerated. P...